Buprenorphine treatment: Factors and first-hand experiences for providers to consider

Journal of Addictive Diseases

Volumn 26, Issue 1, 2007, Pages 3-14

  Meier, Bradley R ^a   Patkar, Ashwin A ^b  

^a Delaware Psychiatric Center   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Buprenorphine; FDA; Opiate dependence; Suboxone ; Subulex

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; OPIATE;

ARTICLE; DRUG COST; DRUG SUBSTITUTION; FINANCIAL MANAGEMENT; HUMAN; MAINTENANCE DRUG DOSE; MEDICAL INFORMATION; MEDICAL PRACTICE; OPIATE ADDICTION; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT SELECTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOTHERAPY; SCREENING TEST; SEDATION; SIDE EFFECT; TREATMENT PLANNING; WITHDRAWAL SYNDROME;

BUPRENORPHINE; CLINICAL COMPETENCE; DRUGS, GENERIC; HEALTH PERSONNEL; HUMANS; MASS SCREENING; MENTAL HEALTH SERVICES; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SOCIOECONOMIC FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34249009901     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v26n01_02     Document Type: Article

References (39)

1. Substance Abuse and Mental Health Services Administration. Report of the Center for Substance Abuse Work Group Federation of State Medical Boards. 2002. http://www.buprenorphine.samhsa.gov/model.html. Last accessed March 21, 2003.
2. Substance Abuse and Mental Health Services Administration. About Buprenorphine Therapy. 2002. http://www.buprenorphine.samhsa.gov/about.html. Last accessed March 17, 2003.
3. Robinson SE. Buprenorphine: An analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Reviews. 2002; 8(4):377-390.
4. Substance Abuse and Mental Health Services Administration. Drug Addiction Treatment Act of 2000 (DATA 2000). 2002. http://buprenorphine.samhsa.gov/ titlexxxv.html. Last accessed Jan 24, 2004.
5. Cowan A. Buprenorphine: New pharmacological aspects. Int J of Clin Prac. Supplement. 2003; 133:3-8.
6. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch of Gen Psych. 1978; 35(4):501-516.
7. Strain EC, Trumble JG, Jara GB. 2001. Use of Buprenorphine in the Pharmacologic Management of Opiod Dependence: A Curriculum for Physicians. Substance Abuse and Mental Health Administration. http://www.buprenorphine. samhsa.gov/Buprenorphine_Curriculum.pdf. Last accessed June 27, 2005.
8. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment including buprenorphine/naloxone. Annals of Parmacotherapy. 2002; 36(2):312-321.
9. US Food and Drug Administration. Subtex and Suboxone Approved to Treat Opiate Dependence. FDA Talk Paper, T02-38. 2002. http://www.fda.gov/bbs/topics/ ANSWERS/2002/ANS01165.html. Last accessed on February 3, 2004.
10. Methadone Centers. Myths and Misconceptions. 2004. http://www. methadonecenters.com/MCmyths.htm. Last accessed on June 27, 2005.
11. Rosenblum A, Magura S, Joseph H. Ambivalence toward methadone treatment among intravenous drug users. J Psychoact Drugs. 1991; 23(1):21-27.
12. Mintzer MZ, Correia CJ, Strain EC. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependant volunteers. Drug and Alcohol Dep. 2004; 74(2):205-209.
13. Wesson DR. Buprenorphine in the treatment of opiate dependence: Its pharmacology and social context of use in the US. J Psychoactive Drugs. Supplement. 2004; 2:119-128.
14. Office of National Drug Control Policy. What America's Users Spend On Illegal Drugs: 1988-1995. Washington, DC: Executive Office of the President. 1997.
15. WESTAT (submitted to The Center for Substance Abuse Treatment). Evaluation of the Buprenorphine Waiver: Summary of Findings From Interviews With Physicians Treating Patients With Buprenorphine. 2004. Author: Rockville, MD.
16. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and Addiction Severity Index. J Clin Psychopharm. 1996; 16(1):58-67.
17. Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology. 2002; 159(2):161-166.
18. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rossler H, Hinterhuber H, Kurz M. Buprenorphine versus methadone maintenance treatment in an ambulant setting: A health-related quality of life assessment. Addiction. 2003; 98(5):693-702.
19. Seifert J, Mezner C, Paetzold W, Borsutszky M, Passie T, Rollnik J, Wiese B, Emrich HM, Schneider U. Detoxification of opiate addicts with multiple drug abuse: A comparison of buprenorphine vs. methadone. Pharmacopsychiatry. 2002; 35(5):159-164.
20. Breen CL, Harris SJ, Lintzeris N, Mattick RP, Hawken L, Bell J, Ritter AJ, Lenne M, Mendoza E. Cessation of methadone maintenance treatment using buprenorphine: Transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dep. 2003; 71:49-55.
21. Greenwald MK, Schuh KJ, Stine SM. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: A preliminary study. Am J Addict. 2003; 12:365-374.
22. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10):949-958.
23. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: A cost-effectiveness analysis. Drug and Alcohol Dep. 2003; 71(3): 295-302.
24. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: A randomized trial. Med J Australia. 2003; 179(1):38-42.
25. Burling Stacey. Addiction drug praised, but its use restricted. The Philadelphia Inquirer. 2005, February 26; A1, A14.
26. Substance Abuse and Mental Health Services Administration. Buprenorphine Physician Locator-Frequently Asked Questions. 2002. http://buprenorphine. samhsa.gov/bwns_locator/physician_faq.htm. Last accessed April 25, 2004.
27. Substance Abuse and Mental Health Services Administration. Buprenorphine Physician Locator. http://buprenorphine.samhsa.gov/bwns_locator/. Last accessed August 18, 2004.
28. Neighmond P. February 27, 2004. Heroin in America: A Special Five-Part Series. National Public Radio. http://www.npr.org/features/feature.php?wfId= 1718079. Accessed on 05/10/04.
29. Feroni I, Peretti-Watel P, Paraponaris A, Masut A, Ronfle E, Mabriez J-C, Yolande O. French general practitioners' attitudes and prescription patterns toward buprenorphine maintained treatment: Does doctor shopping reflect buprenorphine misuse? J Addict Dis. 2005; 24:7-22.
30. Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statements on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004; 27(2):153-159.
31. Anderson N. Letter from Norman Anderson on Buprenorphine Treatment. American Psychological Association, Public Policy Office. http://www.apa.org/ ppo/issues/snbaltr303.html. Last accessed on April 27, 2004.
32. McLellan AT, Luborsky L, Cacciola MA, Griffith BA, Evans F, Barr HL, O'Brien CP. New data from the Addiction Severity Index: Reliability and validity in three centers. J Nervous and Mental Disease. 1985; 173:412-423.
33. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9:199-213.
34. Millon T. The millon inventories: Clinical and personality assessment. New York: Guilford Press; 1997.
35. Millon T, Davis RD. The MCMI-III: Present and future directions. J Personality Assessment. 1997; 68(1):69-85. 35. American Society for Addiction Medicine. Facts. Substance Abuse News and Resource Center. http://www. jointogether.org/plugin.jtml?siteID=ASAM&p=1&Tab=Facts&Object_ID= 258589. Last accessed on April 27, 2004.
36. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology. 2002; 161(2): 202-212.
37. Mannelli P, Gottheil E, Buonanno A, Risio SD. Use of very low-dose naltrexone during opiate detoxification. J Addict Dis. 2003; 22: 63-69.
38. Montoya ID, Schroeder JR, Preston KL, Covi L, Umbricht A, Contoreggi C, Fudala PJ, Paul J, Johnson RE, Gorelick DA. Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat. 2005; 28(3):247-254.
39. Elman BD, Dowd ET. Correlates of burnout in inpatient substance abuse treatment therapists. J Addiction and Offender Counseling. 1997; 17(2):56-65.